Last reviewed · How we verify
Ventilator-acquired pneumonia
Approved treatments
- Zerbaxa · Cubist Pharms
Zerbaxa works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death. - Zosyn · Merck Sharp & Dohme B.V.
Zosyn works by blocking bacterial enzymes that break down antibiotics, allowing the antibiotics to kill bacteria more effectively.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Ventilator-acquired pneumonia patent landscape — cliff calendar, originator estates, attackable patents
- Ventilator-acquired pneumonia treatment landscape brief
- Ventilator-acquired pneumonia treatment updates RSS
Frequently asked questions about Ventilator-acquired pneumonia
What drugs treat Ventilator-acquired pneumonia?
Tracked treatments include Zerbaxa, Zosyn.
What is the treatment for Ventilator-acquired pneumonia?
Standard treatment for Ventilator-acquired pneumonia includes Zerbaxa, Zosyn. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Ventilator-acquired pneumonia patent cliff · Ventilator-acquired pneumonia CI report
- Treatment: Zerbaxa · Cubist Pharms
- Treatment: Zosyn · Merck Sharp & Dohme B.V.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing